drugset / Trial / NCT05089461
A Study to Evaluate the Cardiac Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Malignant Tumor
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, open-label, phase II study to evaluate the cardiac safety of Mitoxantrone Hydrochloride Liposome in patients with advanced malignant tumor who has received at least first-line treatment.
Timeline
- Start
- 2022-03-07
- Primary completion
- 2022-06-20
- Completion
- 2022-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mitoxantrone hydrochloride liposome | Unknown | 20 mg/m2 | Intravenous |